BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma

NCT03943472 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

BIOLOGICAL: Anti-BCMA CAR-T cells
DRUG: Fludarabine
DRUG: Cyclophosphamide
DRUG: Immune inhibitors

Sponsor

Hrain Biotechnology Co., Ltd.

Collaborators

[object Object]